Health Care [ 4/12 ] | Life Sciences Tools & Services [ 21/72 ]
NASDAQ | Common Stock
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
The company operates through two segments, Performance Enzymes and Novel Biotherapeutics.
It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening.
The company also provides biocatalyst screening and protein engineering services.
In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes.
It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency.
The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.
The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 22, 24 | -0.16 Increased by +52.94% | -0.18 Increased by +11.11% |
| Feb 13, 24 | -0.10 Increased by +28.57% | -0.12 Increased by +16.67% |
| Nov 2, 23 | -0.50 Decreased by -233.33% | -0.32 Decreased by -56.25% |
| Aug 3, 23 | -0.17 Decreased by -325.00% | -0.21 Increased by +19.05% |
| May 4, 23 | -0.34 Decreased by -161.54% | -0.31 Decreased by -9.68% |
| Feb 23, 23 | -0.14 Increased by +12.50% | -0.23 Increased by +39.13% |
| Nov 3, 22 | -0.15 Decreased by -600.00% | -0.19 Increased by +21.05% |
| Aug 4, 22 | -0.04 Increased by +42.86% | -0.13 Increased by +69.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 9.28 M Decreased by -73.09% | -34.91 M Decreased by -249.36% | Decreased by -376.29% Decreased by -1.20 K% |
| Jun 30, 23 | 21.32 M Decreased by -44.48% | -11.52 M Decreased by -336.48% | Decreased by -54.04% Decreased by -686.16% |
| Mar 31, 23 | 12.98 M Decreased by -63.27% | -22.62 M Decreased by -170.67% | Decreased by -174.22% Decreased by -636.82% |
| Dec 31, 22 | 30.38 M Increased by +23.97% | -12.61 M Decreased by -23.70% | Decreased by -41.50% Increased by +0.22% |
| Sep 30, 22 | 34.47 M Decreased by -6.25% | -9.99 M Decreased by -545.28% | Decreased by -28.99% Decreased by -574.97% |
| Jun 30, 22 | 38.41 M Increased by +50.89% | -2.64 M Increased by +38.10% | Decreased by -6.87% Increased by +58.98% |
| Mar 31, 22 | 35.34 M Increased by +95.98% | -8.36 M Increased by +7.85% | Decreased by -23.64% Increased by +52.98% |
| Dec 31, 21 | 24.50 M Increased by +16.48% | -10.19 M Decreased by -159.95% | Decreased by -41.59% Decreased by -123.17% |